Search Results - "SEMBA, Hiroshi"

Efficacy and safety of transbronchial microwave ablation therapy under moderate sedation in malignant central airway obstruction patients with respiratory failure: a single-institution retrospective study by Kashiwabara, Kosuke, Fujii, Shinji, Tsumura, Shinsuke, Sakamoto, Kazuhiko, Semba, Hiroshi

“…Background The safety and efficacy of transbronchial microwave ablation (TMA) therapy in patients with malignant central airway obstruction (CAO) with…”
Get full text

Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105 by YAMAMOTO, Nobuyuki, NAKAGAWA, Kazuhiko, SAWA, Toshiyuki, YOKOTA, Soichiro, SETO, Takashi, IMAMURA, Fumio, SAKA, Hideo, IWAMOTO, Yasuo, SEMBA, Hiroshi, CHIBA, Yasutaka, UEJIMA, Hisao, FUKUOKA, Masahiro, NISHIMURA, Yasumasa, TSUJINO, Kayoko, SATOUCHI, Miyako, KUDO, Shinzoh, HIDA, Toyoaki, KAWAHARA, Masaaki, TAKEDA, Koji, KATAKAMI, Nobuyuki

“…This phase III trial of concurrent thoracic radiotherapy (TRT) was conducted to compare third-generation chemotherapy with second-generation chemotherapy in…”
Get full text

Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904) by KUDOH, Shinzoh, TAKEDA, Koji, SETO, Takashi, ANDO, Masahiko, SATOH, Taroh, YOSHIMURA, Naruo, NEGORO, Shunichi, FUKUOKA, Masahiro, NAKAGAWA, Kazuhiko, TAKADA, Minoru, KATAKAMI, Nobuyuki, MATSUI, Kaoru, SHINKAI, Tetsu, SAWA, Toshiyuki, GOTO, Isao, SEMBA, Hiroshi

“…Docetaxel has shown activity in elderly patients with advanced non-small-cell lung cancer (NSCLC). This randomized phase III trial evaluated the efficacy and…”
Get full text

Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters by Endo-Tsukude, Chihiro, Sasaki, Ji-ichiro, Saeki, Sho, Iwamoto, Norihiro, Inaba, Megumi, Ushijima, Sunao, Kishi, Hiroto, Fujii, Shinji, Semba, Hiroshi, Kashiwabara, Kosuke, Tsubata, Yukari, Hayashi, Mitsuhiro, Kai, Yuki, Saito, Hideyuki, Isobe, Takeshi, Kohrogi, Hirotsugu, Hamada, Akinobu

“…Determinants of interindividual variability in erlotinib pharmacokinetics (PK) and adverse events remain to be elucidated. This study with 50 Japanese…”
Get full text

Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB–IIIA non-small cell lung cancer (WJTOG0101) by Yamaguchi, Masafumi, Tada, Hirohito, Mitsudomi, Tetsuya, Seto, Takashi, Yokoi, Kohei, Katakami, Nobuyuki, Nakagawa, Kazuhiko, Oda, Makoto, Ohta, Mitsunori, Sawa, Toshiyuki, Yamashita, Motohiro, Iked, Norihiko, Saka, Hideo, Higashiyama, Masahiko, Nomori, Hiroaki, Semba, Hiroshi, Negoro, Shunichi, Chiba, Yasutaka, Shimokawa, Mototsugu, Fukuoka, Masahiro, Nakanishi, Yoichi

“…Background Adjuvant oral uracil-tegafur (UFT) has led to significantly longer postoperative survival among patients with non-small-cell lung cancer (NSCLC)…”
Get full text

Phase II Trial of Weekly Nab-paclitaxel for Previously Treated Advanced Non–Small Cell Lung Cancer: Kumamoto Thoracic Oncology Study Group (KTOSG) Trial 1301 by Sakata, Shinya, Saeki, Sho, Okamoto, Isamu, Otsubo, Kohei, Komiya, Kazutoshi, Morinaga, Ryotaro, Yoneshima, Yasuto, Koga, Yuichiro, Enokizu, Aimi, Kishi, Hiroto, Hirosako, Susumu, Yamaguchi, Emi, Aragane, Naoko, Fujii, Shinji, Harada, Taishi, Iwama, Eiji, Semba, Hiroshi, Nakanishi, Yoichi, Kohrogi, Hirotsugu

“…Highlights • This is a phase II study of nab-paclitaxel in patients with previously treated NSCLC. • The ORR was 31.7%, which met the primary objective of the…”
Get full text

Phase II study of vinorelbine plus carboplatin with concurrent radiotherapy in elderly patients with non-small cell lung cancer by Yamaguchi, Masafumi, Hirata, Hideki, Ebi, Noriyuki, Araki, Jun, Seto, Takashi, Maruyama, Riichiroh, Akamine, Shinji, Inoue, Yuichi, Semba, Hiroshi, Sasaki, Jiichiro, Okamoto, Tatsuro

“…Abstract Objective Concurrent chemoradiotherapy is the standard treatment for locally advanced non-small cell lung cancer. In the current aging society, the…”
Get full text

Additional bevacizumab in EGFR-mutant lung adenocarcinoma patients who had oligo-progression after the failure of EGFR-TKI: A single-institute retrospective study by Kashiwabara, Kosuke, Fujii, Shinji, Tsumura, Shinsuke, Sakamoto, Kazuhiko, Semba, Hiroshi

“…In EGFR-mutant NSCLC patients with oligo-progression disease (oligo-PD) after the EGFR-TKI failure, additional local ablative therapy (LAT) including…”
Get full text

Tolerability and efficacy of afatinib at a low starting dosage in 10 elderly or low performance status patients with advanced refractory non-small-cell lung cancer by Kashiwabara, Kosuke, Semba, Hiroshi, Fujii, Shinji, Tsumura, Shinsuke

“…Abstract Background Whether a full dosage of afatinib is tolerable and effective for elderly or low performance status (PS) patients with advanced refractory…”
Get full text

Current status and future perspectives of cooperative study groups for lung cancer in Japan by Kawano, Yuko, Okamoto, Isamu, Fukuda, Haruhiko, Ohe, Yuichiro, Nakamura, Shinichiro, Nakagawa, Kazuhiko, Hotta, Katsuyuki, Kiura, Katsuyuki, Takiguchi, Yuichi, Saka, Hideo, Okamoto, Hiroaki, Takayama, Koichi, Semba, Hiroshi, Kobayashi, Kunihiko, Kenmotsu, Hirotsugu, Tsuboi, Masahiro, Yamamoto, Nobuyuki, Nukiwa, Toshihiro, Nakanishi, Yoichi

“…Abstract The performance of scientifically and ethically valid prospective clinical trials is the only means by which to obtain reliable clinical evidence that…”
Get full text

Catheter drainage followed by the instillation of bleomycin to manage malignant pericardial effusion in non-small cell lung cancer: a multi-institutional phase II trial by Maruyama, Riichiroh, Yokoyama, Hideki, Seto, Takashi, Nagashima, Seiji, Kashiwabara, Kosuke, Araki, Jun, Semba, Hiroshi, Ichinose, Yukito

“…Malignant pericardial effusion (MPE) causes cardiac tamponade and an extremely poor outcome unless it is well controlled. The effect of pericardial drainage…”
Get more information

Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer : Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters by Chihiro Endo-Tsukudea, b, c, Ji-ichiro Sasakid, Sho Saekie, Norihiro Iwamotof, Megumi Inabag, Sunao Ushijimag, Hiroto Kishih, Shinji Fujiii, Hiroshi Sembai, Kosuke Kashiwabaraj, Yukari Tsubatak, Mitsuhiro Hayashib, Yuki Kaia, Hideyuki Saitoa, e, Takeshi Isobek, Hirotsugu Kohrogia, Akinobu Hamadaa

“…Determinants of interindividual variability in erlotinib pharmacokinetics (PK) and adverse events remain to be elucidated. This study with 50 Japanese…”
Get full text

A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706 by Takeda, Koji, Negoro, Shunichi, Tanaka, Masahiro, Fukuda, Haruhiko, Nakagawa, Kazuhiko, Kawahara, Masaaki, Semba, Hiroshi, Kudoh, Shinzoh, Sawa, Toshiyuki, Saijo, Nagahiro, Fukuoka, Masahiro

“…It is important to identify optimal regimens of cisplatin-based, third-generation chemotherapy and thoracic radiotherapy for patients with unresectable, Stage…”
Get full text

Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease by Kashiwabara, Kosuke, Semba, Hiroshi, Fujii, Shinji, Tsumura, Shinsuke

“…Purpose Several non-small cell lung cancer (NSCLC) cases of successful rechallenge with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)…”
Get full text

Complications associated with endobronchial ultrasound-guided transbronchial needle aspiration: a nationwide survey by the Japan Society for Respiratory Endoscopy by Asano, Fumihiro, Aoe, Motoi, Ohsaki, Yoshinobu, Okada, Yoshinori, Sasada, Shinji, Sato, Shigeki, Suzuki, Eiichi, Semba, Hiroshi, Fukuoka, Kazuya, Fujino, Shozo, Ohmori, Kazumitsu

“…With the recent widespread use of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), there have been occasional reports on…”
Get full text

The overall survival in patients with medically inoperable stage I NSCLC that recurred after radical radiotherapy by Kashiwabara, Kosuke, Fujii, Shinji, Tsumura, Shinsuke, Semba, Hiroshi

Get full text

P2-115The overall survival in patients with medically inoperable stage I NSCLC that recurred after radical radiotherapy by Kashiwabara, Kosuke, Fujii, Shinji, Tsumura, Shinsuke, Semba, Hiroshi

Get full text

Preoperative Percutaneous Transthoracic Needle Biopsy Increased the Risk of Pleural Recurrence in Pathological Stage I Lung Cancer Patients With Sub-pleural Pure Solid Nodules by Kashiwabara, Kosuke, Semba, Hiroshi, Fujii, Shinji, Tsumura, Shinsuke

“…We retrospectively evaluated whether preoperative percutaneous transthoracic needle biopsy (PTNB) affected the incidence of pleural recurrence in pathological…”
Get full text

Uracil/Tegafur Plus Cisplatin with Concurrent Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer by Ichinose, Yukito, Nakai, Yushi, Kudoh, Shoji, Semba, Hiroshi, Yoshida, Susumu, Nukiwa, Toshihiro, Yamamoto, Hidehiko, Yamane, Yoshio, Niitani, Hisanobu

“…Purpose: To evaluate the efficacy and toxicity of a novel combination treatment using concurrent radiotherapy with cisplatin plus UFT, which is comprised of…”
Get full text

Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a phase II study by Seto, Takashi, Takezako, Yoriko, Nakamura, Hiroko, Takeda, Kayo, Inoue, Fumiko, Semba, Hiroshi, Eguchi, Kenji

“…To evaluate the safety and efficacy of second-line chemotherapy with docetaxel and cisplatin for non-small cell lung cancer (NSCLC), we performed a phase II…”
Get full text